瞄准创新,打造“新康哲”。来源|医药研究社康哲药业创新药商业化已拉开大幕,只是“新旧康哲”转换难免阵痛。根据康哲药业最新发布的财报,2024年,公司实现营业收入74.69亿元,同比下降6.79%,归属母公司净利润16.20亿元,同比下降32.54%。这也延续了2023年的业绩下滑态势。从产品端来看,2024年,公司拥有的3款原研药(黛力新、波依定与优思弗)参与了国家带量采购,但均未中标,上述产品全...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.